Cormorant Asset Management, LP Neurocrine Biosciences Inc Transaction History

Cormorant Asset Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $2.13 Million - $3.26 Million	-25,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $1.07 Million - $1.63 Million	-14,300 Reduced 36.39%	25,000 $2.16 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $896,873 - $1.09 Million	-10,700 Reduced 21.4%	39,300 $3.54 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $2.89 Million - $3.65 Million	-40,000 Reduced 44.44%	50,000 $4.22 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $8.89 Million - $11.7 Million	-128,222 Reduced 58.76%	90,000 $7.93 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $2.95 Million - $5.38 Million	43,222 Added 24.7%	218,222 $15.6 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $1.59 Million - $2.03 Million	-16,112 Reduced 8.43%	175,000 $21.5 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $674,421 - $821,517	-8,888 Reduced 4.44%	191,112 $15.8 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $2.93 Million - $3.88 Million	-50,000 Reduced 20.0%	200,000 $15.5 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $12 Million - $15.3 Million	250,000	250,000 $15.3 Million

625

95.2M

661K

227K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.